Neoantigen × AI
Daily research signal
36Brief

IgGM2 Unifies Immune Receptor Design With Non-canonical Neoantigens

The neoantigen landscape is expanding beyond canonical mutations to include non-canonical and therapy-induced sources, offering new targets for low-tumor-burden cancers.Frontiers

Simultaneously, IgGM2 introduces a unified all-atom foundation model that jointly designs immune receptor structures and sequences, addressing key limitations in current adaptive immune receptor design pipelines.bioRxiv

1new story1 in context
AI / MethodsyesterdayNew

IgGM2: An All-Atom Foundation Model for Adaptive Immune Receptor Design

IgGM2 is a new all-atom foundation model for adaptive immune receptor design that jointly generates CDR residue identities and full-atom structures. Unlike modular pipelines, it uses a structure-to-design strategy to allow framework geometry to adapt to designed CDRs without separate inverse folding. This unified approach aims to improve accuracy in modeling the coupled variation of sequence, conformation, and binding geometry for antibodies and TCRs.

biorxiv · yesterday · Ma, J.; Wu, F.; Yao, L.; Gao, J.; Wang, R.; Li, Q.; Yang, N.; Jiang, S.; Huang, D.; Pan, X

01

Relevant work from earlier we're still surfacing — not today's news.